Hologicvs.Natera
HOLX vs NTRA · both in Diagnostics, part of the Medicine, pharma & life science value chain: Tests, imaging and assays that support clinical decision-making.
Natera is about 3.3× larger than Hologic by market cap; year to date, Natera leads (+72.7% vs +2.0%).
Side by side
| HOLX | NTRA | |
|---|---|---|
| Market cap | $17B | $55.6B |
| Price | — | $390.79 |
| Today | — | −1.2% |
| Return YTD | +2.0% | +72.7% |
| Return 1Y | −3.5% | +134.7% |
| P/E | 31.2 | — |
| P/S | 4.1 | 20.5 |
| P/B | 3.2 | 30.5 |
Data as of 2026-10-08 · updates daily after U.S. close
The two companies
HologicHOLX
Women's health defines the range here, from molecular diagnostic tests to mammography systems and surgical products.
Full HOLX profile →NateraNTRA
Genetic testing put to three uses: Panorama screens pregnancies, Signatera works in oncology, and a third line covers transplant medicine.
Full NTRA profile →More HOLX & NTRA comparisons
Other head-to-heads in the Diagnostics segment.
See where HOLX and NTRA sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →